Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: Briquilimab
DRUG: Filgrastim
DRUG: Abatacept
DRUG: Sirolimus
DRUG: Cyclophosphamide

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)